Department of Psychiatry, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore 560029, India.
Asian J Psychiatr. 2013 Dec;6(6):544-7. doi: 10.1016/j.ajp.2013.07.007. Epub 2013 Aug 22.
We examined the effect of atomoxetine supplementation in treated-as-usual patients with alcohol, tobacco and other drug dependence (ATOD) and co-morbid externalizing symptoms (ES).
Subjects were selected from a substance dependence treatment-cohort and assessed for: (a) high ES counts, (b) maximum prior period of abstinence, (c) quality of life during that period, and (d) shortest time from prior relapse to restarting treatment. Subjects were prescribed atomoxetine and followed up to their first relapse.
Out of 262 subjects screened during the study period (March-April 2008), 18 subjects who fulfilled eligibility criteria were recruited. All subjects were male, with early onset of substance dependence to at least two substances. Atomoxetine treatment led to significant treatment benefits: ES reduction, longer abstinence, shorter turnaround time and better quality of life.
Atomoxetine has a potential role in the treatment of early onset ATOD patients with ES, as an adjuvant to the standard treatment.
我们研究了托莫西汀补充治疗对伴有共病外显症状（ES）的酒精、烟草和其他药物依赖（ATOD）患者的治疗效果。
从物质依赖治疗队列中选择受试者，并评估：（a）高 ES 计数，（b）最长的既往禁欲期，（c）该期间的生活质量，以及（d）从上次复发到重新开始治疗的最短时间。为受试者开具托莫西汀处方，并随访至首次复发。
在研究期间（2008 年 3 月至 4 月）共筛选了 262 名受试者，有 18 名符合入选标准的受试者被纳入。所有受试者均为男性，物质依赖的发病年龄至少为两种物质。托莫西汀治疗可显著获益：ES 减少、更长的禁欲期、更短的恢复时间和更好的生活质量。
托莫西汀作为标准治疗的辅助手段，可能在治疗伴有 ES 的早期起病 ATOD 患者方面有一定作用。
